Edition:
United Kingdom

Assembly Biosciences Inc (ASMB.OQ)

ASMB.OQ on NASDAQ Stock Exchange Global Select Market

15.61USD
24 May 2019
Change (% chg)

$0.51 (+3.38%)
Prev Close
$15.10
Open
$15.10
Day's High
$15.69
Day's Low
$15.10
Volume
48,025
Avg. Vol
91,792
52-wk High
$48.62
52-wk Low
$13.13

Latest Key Developments (Source: Significant Developments)

Assembly Biosciences Q1 Loss Per Share $1.05
Thursday, 9 May 2019 

May 9 (Reuters) - Assembly Biosciences Inc ::ASSEMBLY BIOSCIENCES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q1 LOSS PER SHARE $1.05.Q1 EARNINGS PER SHARE ESTIMATE $-1.04 -- REFINITIV IBES DATA.  Full Article

Assembly Biosciences Announces Changes To Senior Leadership Team
Thursday, 2 May 2019 

May 2 (Reuters) - Assembly Biosciences Inc ::ASSEMBLY BIOSCIENCES ANNOUNCES CHANGES TO SENIOR LEADERSHIP TEAM.ASSEMBLY BIOSCIENCES INC - DEPARTURE OF GRAHAM COOPER, CHIEF FINANCIAL OFFICER AND CHIEF OPERATING OFFICER.ASSEMBLY BIOSCIENCES INC - GRAHAM COOPER IS LEAVING TO PURSUE OTHER INTERESTS.ASSEMBLY BIOSCIENCES - INITIATED SEARCH FOR NEW CFO, MICHAEL SAMAR, APPOINTED AS PRINCIPAL ACCOUNTING OFFICER,ASSUMED SOME OF COOPER'S RESPONSIBILITIES.  Full Article

Armistice Capital Llc Reports A 6.6 Percent Passive Stake In Assembly Biosciences Inc As Of April 15, 2019
Thursday, 25 Apr 2019 

April 25 (Reuters) - Assembly Biosciences Inc ::ARMISTICE CAPITAL LLC REPORTS A 6.6 PERCENT PASSIVE STAKE IN ASSEMBLY BIOSCIENCES INC AS OF APRIL 15, 2019 - SEC FILING.  Full Article

Assembly Biosciences Says ABI-H3733 Demonstrated Enhanced Potency In Preclinical Studies
Thursday, 11 Apr 2019 

April 11 (Reuters) - Assembly Biosciences Inc ::ASSEMBLY BIOSCIENCES INC - ABI-H3733 DEMONSTRATED ENHANCED POTENCY IN PRECLINICAL STUDIES.ASSEMBLY BIOSCIENCES INC - PHASE 1A STUDY OF ABI-H2158 DEMONSTRATED SAFETY, TOLERABILITY AND ACHIEVEMENT OF TARGET LIVER CONCENTRATIONS.ASSEMBLY BIOSCIENCES INC - ABI-H3733 DEMONSTRATED ENHANCED POTENCY IN PRECLINICAL STUDIES.  Full Article

Assembly Biosciences Reports Fourth Quarter And Year End 2018 Financial Results
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Assembly Biosciences Inc ::ASSEMBLY BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.03.Q4 EARNINGS PER SHARE ESTIMATE $-0.91 -- REFINITIV IBES DATA.REVENUES CONSISTING OF REVENUE FROM COLLABORATIVE RESEARCH WERE ABOUT $3.7 MILLION FOR 3-MONTHS ENDED DEC 31, 2018 VERSUS $3.3 MILLION.Q4 REVENUE VIEW $4.2 MILLION -- REFINITIV IBES DATA.  Full Article

Assembly Biosciences Announces Completion Of Enrollment In Two Phase 2A Studies
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Assembly Biosciences Inc ::ASSEMBLY BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT IN TWO PHASE 2A STUDIES WITH ABI-H0731 FOR CHRONIC HEPATITIS B VIRUS.ASSEMBLY BIOSCIENCES INC - ANTICIPATES REPORTING INTERIM RESULTS FROM BOTH STUDIES DURING Q2 OF 2019.ASSEMBLY BIOSCIENCES INC - DATA FROM ABI-2158 STUDY IS EXPECTED TO BE AVAILABLE IN FIRST HALF OF 2019.ASSEMBLY BIOSCIENCES INC - PLANNING TO ADVANCE ITS THIRD CORE INHIBITOR, ABI-H3733, INTO CLINICAL TRIALS IN 2019.  Full Article

Assembly Biosciences Q3 Loss Per Share $0.87
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Assembly Biosciences Inc ::ASSEMBLY BIOSCIENCES ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES HBV PROGRAM UPDATE.Q3 LOSS PER SHARE $0.87.Q3 EARNINGS PER SHARE VIEW $-1.03 -- THOMSON REUTERS I/B/E/S.  Full Article

Assembly Biosciences Says Graham Cooper Joined Assembly As New CFO And COO Effective March 8​
Monday, 12 Mar 2018 

March 12 (Reuters) - Assembly Biosciences Inc ::ASSEMBLY BIOSCIENCES ANNOUNCES ADDITIONS TO MANAGEMENT TEAM AND BOARD OF DIRECTORS.ASSEMBLY BIOSCIENCES INC - ‍GRAHAM COOPER JOINED ASSEMBLY AS ITS NEW CFO AND COO EFFECTIVE MARCH 8​.  Full Article

Assembly Biosciences Files For Mixed Shelf Of Up To $250 Mln
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Assembly Biosciences Inc ::ASSEMBLY BIOSCIENCES FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING.  Full Article

Assembly Biosciences prices public offering of 2.21 mln common shares at $27.25 per share
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Assembly Biosciences Inc :Assembly biosciences announces pricing of $60 million offering of common stock.Says public offering of 2.21 million common shares priced at $27.25 per share.  Full Article